AbCellera's Menopause Drug Hits Phase 2 Goals, Best-in-Class Potential
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera's ABCL635 met its primary efficacy endpoints in a Phase 2 trial for vasomotor symptoms (hot flashes) due to menopause, showing significant reductions in frequency and severity at week 4 after a single dose. The company claims best-in-class results, with additional benefits in sleep and patient-reported improvement. The drug was well-tolerated with no serious adverse events. This is the first clinical validation of AbCellera's internal pipeline, shifting the narrative from a platform company to one with a potentially valuable product. The data release follows the August 7th announcement that results were imminent, and comes amid a strong cash position bolstered by recent Jazz and Vertex collaborations. A pivotal Phase 3 program is the next major catalyst. The stock is up 32% on the good news.
At the time of this announcement, ABCL was trading at $9.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.75 to $8.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.